58 results on '"Nancarrow DJ"'
Search Results
2. Additional support for schizophrenia linkage on chromosomes 6 and 8: A multicenter study
- Author
-
Levinson, DF, Wildenauer, DB, Schwab, SG, Albus, M, Hallmayer, J, Lerer, B, Maier, W, Blackwood, D, Muir, W, StClair, D, Morris, S, Moises, HW, Yang, L, Kristbjarnarson, H, Helgason, T, Wiese, C, Collier, DA, Holmans, P, Daniels, J, Rees, M, Asherson, P, Roberts, Q, Cardno, A, Arranz, MJ, Vallada, H, McGuffin, D, Owen, MJ, Pulver, AE, Antonarakis, SE, Babb, R, Blouin, JL, DeMarchi, N, Dombroski, B, Housman, D, Karayiorgou, M, Ott, J, Kasch, L, Kazazian, H, Lasseter, VK, Loetscher, E, Luebbert, H, Nestadt, G, Ton, C, Wolyniec, PS, Laurent, C, deChaldee, M, Thibaut, F, Jay, M, Samolyk, D, Petit, M, Campion, D, Mallet, J, Straub, RE, MacLean, CJ, Easter, SM, ONeill, FA, Walsh, D, Kendler, KS, Gejman, PV, Gershon, E, Badner, J, Beshah, E, Zhang, J, Riley, BP, Rajagopalan, S, MogudiCarter, M, Jenkins, T, Williamson, R, DeLisi, LE, Garner, C, Kelly, M, LeDuc, C, Cardon, L, Lichter, J, Harris, T, Loftus, J, Shields, G, Comasi, M, Vita, A, Smith, A, Dann, J, Joslyn, G, Gurling, H, Kalsi, G, Brynjolfsson, J, Curtis, D, Sigmundsson, T, Butler, R, Read, T, Murphy, P, Chen, ACH, Petursson, H, Byerley, B, Hoff, M, Holik, J, Coon, H, Nancarrow, DJ, Crowe, RR, Andreasen, N, Silverman, JM, Mohs, RC, Siever, LJ, Endicott, J, Sharpe, L, Lennon, DP, Hayward, NK, Sandkuijl, LA, Mowry, BJ, Aschauer, HN, Meszaros, K, Lenzinger, E, Fuchs, K, Heiden, AM, Kruglyak, L, Daly, MJ, and Matise, TC
- Subjects
genotype ,RELATIVES ,DNA MARKERS ,POTENTIAL LINKAGE ,ILLNESS ,collaboration ,polymorphism ,AFFECTIVE-DISORDERS ,schizophrenia ,SIB-PAIR LINKAGE ,SUSCEPTIBILITY GENES ,genetic linkage ,GENOME-WIDE SEARCH ,LOCUS ,HETEROGENEITY - Abstract
In response to reported schizophrenia linkage findings on chromosomes 3, 6 and 8, fourteen research groups genotyped 14 microsatellite markers in an unbiased, collaborative (New) sample of 403-567 informative pedigrees per marker, and in the Original sample which produced each finding (the Johns Hopkins University sample of 40-52 informative pedigrees for chromosomes 3 and 8, and the Medical College of Virginia sample of 156-191 informative pedigrees for chromosome 6). Primary planned analyses (New sample) were two-point heterogeneity lod score (lod2) tests (dominant and recessive affected-only models), and multipoint affected sibling pair (ASP) analysis, with a narrow diagnostic model schizophrenia and schizoaffective disorders), Regions with positive results were also analyzed in the Original and Combined samples. There was no evidence for linkage on chromosome 3. For chromosome 6, ASP maximum lod scores (MLS) were 2.19 (New sample, nominal p = .001) and. 2.68 (Combined sample, p = .0004). For chromosome 8, maximum lod2 scores (tests of linkage with heterogeneity) were 2.22 (New sample, p = .0014) and 3.06 (Combined sample, p = .00018). Results are interpreted as inconclusive hut suggestive of linkage in the latter two regions. We discuss possible reasons for failing to achieve a conclusive result in this large sample, Design issues and limitations of this type of collaborative study are discussed, and it is concluded that multicenter follow-up linkage studies of complex disorders can help to direct research efforts toward promising regions.
- Published
- 1996
3. SCHIZOPHRENIA SUSCEPTIBILITY AND CHROMOSOME 6P24-22
- Author
-
MOWRY, BJ, NANCARROW, DJ, LENNON, DP, SANDKUIJL, LA, CROWE, RR, SILVERMAN, JM, MOHS, RC, SIEVER, LJ, ENDICOTT, J, SHARPE, L, WALTERS, MK, HAYWARD, NK, and LEVINSON, DF
- Subjects
DISORDERS ,DIAGNOSTIC INTERVIEW ,HUMANS ,MULTILOCUS LINKAGE ANALYSIS ,SCHEDULE - Published
- 1995
4. ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.
- Author
-
McEwen DP, Ray P, Nancarrow DJ, Wang Z, Kasturirangan S, Abdullah S, Balan A, Hoskeri R, Thomas D, Lawrence TS, Beer DG, Lagisetty KH, and Ray D
- Subjects
- Humans, Male, T-Lymphocytes metabolism, T-Lymphocytes immunology, Female, Gene Expression Regulation, Neoplastic, Barrett Esophagus pathology, Barrett Esophagus genetics, Barrett Esophagus metabolism, Middle Aged, Esophageal Neoplasms genetics, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Esophageal Neoplasms metabolism, Esophageal Neoplasms immunology, Adenocarcinoma genetics, Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma metabolism, Adenocarcinoma immunology, CD3 Complex metabolism, CD3 Complex genetics, Cytokines metabolism, Ubiquitins metabolism, Ubiquitins genetics
- Abstract
Immunosuppression is a common feature of esophageal adenocarcinoma (EAC) and has been linked to poor overall survival (OS). We hypothesized that upstream factors might negatively influence CD3 levels and T cell activity, thus promoting immunosuppression and worse survival. We used clinical data and patient samples of those who progressed from Barrett's to dysplasia to EAC, investigated gene (RNA-Seq) and protein (tissue microarray) expression, and performed cell biology studies to delineate a pathway impacting CD3 protein stability that might influence EAC outcome. We showed that the loss of both CD3-ε expression and CD3+ T cell number correlated with worse OS in EAC. The gene related to anergy in lymphocytes isoform 1 (GRAIL1), which is the prominent isoform in EACs, degraded (ε, γ, δ) CD3s and inactivated T cells. In contrast, isoform 2 (GRAIL2), which is reduced in EACs, stabilized CD3s. Further, GRAIL1-mediated CD3 degradation was facilitated by interferon-stimulated gene 15 (ISG15), a ubiquitin-like protein. Consequently, the overexpression of a ligase-dead GRAIL1, ISG15 knockdown, or the overexpression of a conjugation-defective ISG15-leucine-arginine-glycine-glycine mutant could increase CD3 levels. Together, we identified an ISG15/GRAIL1/mutant p53 amplification loop negatively influencing CD3 levels and T cell activity, thus promoting immunosuppression in EAC.
- Published
- 2024
- Full Text
- View/download PDF
5. Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.
- Author
-
Kasturirangan S, Nancarrow DJ, Shah A, Lagisetty KH, Lawrence TS, Beer DG, and Ray D
- Subjects
- Humans, Ubiquitination, Protein Isoforms genetics, Protein Isoforms metabolism, Carcinogenesis, Tumor Suppressor Proteins metabolism, Ubiquitin-Protein Ligases metabolism, Gastrointestinal Neoplasms genetics
- Abstract
The advancement of RNAseq and isoform-specific expression platforms has led to the understanding that isoform changes can alter molecular signaling to promote tumorigenesis. An active area in cancer research is uncovering the roles of ubiquitination on spliceosome assembly contributing to transcript diversity and expression of alternative isoforms. However, the effects of isoform changes on functionality of ubiquitination machineries (E1, E2, E3, E4, and deubiquitinating (DUB) enzymes) influencing onco- and tumor suppressor protein stabilities is currently understudied. Characterizing these changes could be instrumental in improving cancer outcomes via the identification of novel biomarkers and targetable signaling pathways. In this review, we focus on highlighting reported examples of direct, protein-coded isoform variation of ubiquitination enzymes influencing cancer development and progression in gastrointestinal (GI) malignancies. We have used a semi-automated system for identifying relevant literature and applied established systems for isoform categorization and functional classification to help structure literature findings. The results are a comprehensive snapshot of known isoform changes that are significant to GI cancers, and a framework for readers to use to address isoform variation in their own research. One of the key findings is the potential influence that isoforms of the ubiquitination machinery have on oncoprotein stability., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
6. Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis.
- Author
-
Hinton T, Karnak D, Tang M, Jiang R, Luo Y, Boonstra P, Sun Y, Nancarrow DJ, Sandford E, Ray P, Maurino C, Matuszak M, Schipper MJ, Green MD, Yanik GA, Tewari M, Naqa IE, Schonewolf CA, Haken RT, Jolly S, Lawrence TS, and Ray D
- Abstract
Grade 2 and higher radiation pneumonitis (RP2) is a potentially fatal toxicity that limits efficacy of radiation therapy (RT). We wished to identify a combined biomarker signature of circulating miRNAs and cytokines which, along with radiobiological and clinical parameters, may better predict a targetable RP2 pathway. In a prospective clinical trial of response-adapted RT for patients (n = 39) with locally advanced non-small cell lung cancer, we analyzed patients' plasma, collected pre- and during RT, for microRNAs (miRNAs) and cytokines using array and multiplex enzyme linked immunosorbent assay (ELISA), respectively. Interactions between candidate biomarkers, radiobiological, and clinical parameters were analyzed using data-driven Bayesian network (DD-BN) analysis. We identified alterations in specific miRNAs (miR-532, -99b and -495, let-7c, -451 and -139-3p) correlating with lung toxicity. High levels of soluble tumor necrosis factor alpha receptor 1 (sTNFR1) were detected in a majority of lung cancer patients. However, among RP patients, within 2 weeks of RT initiation, we noted a trend of temporary decline in sTNFR1 (a physiological scavenger of TNFα) and ADAM17 (a shedding protease that cleaves both membrane-bound TNFα and TNFR1) levels. Cytokine signature identified activation of inflammatory pathway. Using DD-BN we combined miRNA and cytokine data along with generalized equivalent uniform dose (gEUD) to identify pathways with better accuracy of predicting RP2 as compared to either miRNA or cytokines alone. This signature suggests that activation of the TNFα-NFκB inflammatory pathway plays a key role in RP which could be specifically ameliorated by etanercept rather than current therapy of non-specific leukotoxic corticosteroids., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
7. UBCH5 Family Members Differentially Impact Stabilization of Mutant p53 via RNF128 Iso1 During Barrett's Progression to Esophageal Adenocarcinoma.
- Author
-
Ray P, Nancarrow DJ, Ferrer-Torres D, Wang Z, San Martinho M, Hinton T, Wu JH, Wu A, Turgeon DK, Hammer MA, Dame MK, Lawrence TS, O'Brien PJ, Spence JR, Beer DG, and Ray D
- Subjects
- Disease Progression, Humans, Adenocarcinoma pathology, Barrett Esophagus genetics, Barrett Esophagus pathology, Esophageal Neoplasms pathology, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Ubiquitin-Conjugating Enzymes genetics, Ubiquitin-Conjugating Enzymes metabolism, Ubiquitin-Protein Ligases genetics, Ubiquitin-Protein Ligases metabolism
- Abstract
Background & Aims: TP53 mutations underlie Barrett's esophagus (BE) progression to dysplasia and cancer. During BE progression, the ubiquitin ligase (E3) RNF128/GRAIL switches expression from isoform 2 (Iso2) to Iso1, stabilizing mutant p53. However, the ubiquitin-conjugating enzyme (E2) that partners with Iso1 to stabilize mutant p53 is unknown., Methods: Single-cell RNA sequencing of paired normal esophagus and BE tissues identified candidate E2s, further investigated in expression data from BE to esophageal adenocarcinoma (EAC) progression samples. Biochemical and cellular studies helped clarify the role of RNF128-E2 on mutant p53 stability., Results: The UBE2D family member 2D3 (UBCH5C) is the most abundant E2 in normal esophagus. However, during BE to EAC progression, loss of UBE2D3 copy number and reduced expression of RNF128 Iso2 were noted, 2 known p53 degraders. In contrast, expression of UBE2D1 (UBCH5A) and RNF128 Iso1 in dysplastic BE and EAC forms an inactive E2-E3 complex, stabilizing mutant p53. To destabilize mutant p53, we targeted RNF128 Iso1 either by mutating asparagine (N48, 59, and 101) residues to block glycosylation to facilitate β-TrCP1-mediated degradation or by mutating proline (P54 and 105) residues to restore p53 polyubiquitinating ability. In addition, either loss of UBCH5A catalytic activity, or disruption of the Iso1-UBCH5A interaction promoted Iso1 loss. Consequently, overexpression of either catalytically dead or Iso1-binding-deficient UBCH5A mutants destabilized Iso1 to degrade mutant p53, thus compromising the clonogenic survival of mutant p53-dependent BE cells., Conclusions: Loss of RNF128 Iso2-UBCH5C and persistence of the Iso1-UBCH5A complex favors mutant p53 stability to promote BE cell survival. Therefore, targeting of Iso1-UBCH5A may provide a novel therapeutic strategy to prevent BE progression., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
8. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
- Author
-
Lagisetty KH, McEwen DP, Nancarrow DJ, Schiebel JG, Ferrer-Torres D, Ray D, Frankel TL, Lin J, Chang AC, Kresty LA, and Beer DG
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Barrett Esophagus genetics, Barrett Esophagus pathology, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes pathology, Chemokines genetics, Chemokines metabolism, Cytokines genetics, Cytokines metabolism, Disease Progression, Esophageal Neoplasms genetics, Esophageal Neoplasms pathology, Humans, Immune Tolerance, Immunohistochemistry, Interleukin-6 genetics, Interleukin-6 metabolism, Interleukin-8 genetics, Interleukin-8 metabolism, Macrophages immunology, Macrophages pathology, RNA-Seq, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory pathology, Tumor Microenvironment genetics, Tumor Microenvironment immunology, Adenocarcinoma immunology, Barrett Esophagus immunology, Esophageal Neoplasms immunology
- Abstract
Esophageal adenocarcinoma (EAC) develops from Barrett's esophagus (BE), a chronic inflammatory state that can progress through a series of transformative dysplastic states before tumor development. While molecular and genetic changes of EAC tumors have been studied, immune microenvironment changes during Barrett's progression to EAC remain poorly understood. In this study, we identify potential immunologic changes that can occur during BE-to-EAC progression. RNA sequencing (RNA-Seq) analysis on tissue samples from EAC patients undergoing surgical resection demonstrated that a subset of chemokines and cytokines, most notably IL6 and CXCL8, increased during BE progression to EAC. xCell deconvolution analysis investigating immune cell population changes demonstrated that the largest changes in expression during BE progression occurred in M2 macrophages, pro-B cells, and eosinophils. Multiplex immunohistochemical staining of tissue microarrays showed increased immune cell populations during Barrett's progression to high-grade dysplasia. In contrast, EAC tumor sections were relatively immune poor, with a rise in PD-L1 expression and loss of CD8+ T cells. These data demonstrate that the EAC microenvironment is characterized by poor cytotoxic effector cell infiltration and increased immune inhibitory signaling. These findings suggest an immunosuppressive microenvironment, highlighting the need for further studies to explore immune modulatory therapy in EAC.
- Published
- 2021
- Full Text
- View/download PDF
9. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers.
- Author
-
Martinho MS, Nancarrow DJ, Lawrence TS, Beer DG, and Ray D
- Subjects
- Antineoplastic Agents therapeutic use, Gastrointestinal Neoplasms drug therapy, Gastrointestinal Neoplasms pathology, Humans, Molecular Chaperones antagonists & inhibitors, Molecular Targeted Therapy methods, Mutation, Protein Stability drug effects, Proteolysis drug effects, Tumor Suppressor Protein p53 metabolism, Ubiquitin-Protein Ligases antagonists & inhibitors, Antineoplastic Agents pharmacology, Gastrointestinal Neoplasms genetics, Molecular Chaperones metabolism, Tumor Suppressor Protein p53 genetics, Ubiquitin-Protein Ligases metabolism
- Abstract
The incidence of esophageal adenocarcinoma (EAC) and other gastrointestinal (GI) cancers have risen dramatically, thus defining the oncogenic drivers to develop effective therapies are necessary. Patients with Barrett's Esophagus (BE), have an elevated risk of developing EAC. Around 70%-80% of BE cases that progress to dysplasia and cancer have detectable TP53 mutations. Similarly, in other GI cancers higher rates of TP53 mutation are reported, which provide a significant survival advantage to dysplastic/cancer cells. Targeting molecular chaperones that mediate mutant p53 stability may effectively induce mutant p53 degradation and improve cancer outcomes. Statins can achieve this via disrupting the interaction between mutant p53 and the chaperone DNAJA1, promoting CHIP-mediated degradation of mutant p53, and statins are reported to significantly reduce the risk of BE progression to EAC. However, statins demonstrated sub-optimal efficacy depending on cancer types and TP53 mutation specificity. Besides the well-established role of MDM2 in p53 stability, we reported that individual isoforms of the E3 ubiquitin ligase GRAIL (RNF128) are critical, tissue-specific regulators of mutant p53 stability in BE progression to EAC, and targeting the interaction of mutant p53 with these isoforms may help mitigate EAC development. In this review, we discuss the critical ubiquitin-proteasome and chaperone regulation of mutant p53 stability in EAC and other GI cancers with future insights as to how to affect mutant p53 stability, further noting how the precise p53 mutation may influence the efficacy of treatment strategies and identifying necessary directions for further research in this field., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Correction to "Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application".
- Author
-
Ma X, Kang X, He L, Zhou J, Zhou J, Sturm MB, Beer DG, Kuick R, Nancarrow DJ, Appelman HD, Pang Z, Li W, Zhang C, Zhang W, Zhang Y, Wang TD, and Li M
- Published
- 2019
- Full Text
- View/download PDF
11. Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application.
- Author
-
Ma X, Kang X, He L, Zhou J, Zhou J, Sturm MB, Beer DG, Kuick R, Nancarrow DJ, Appelman HD, Pang Z, Li W, Zhang C, Zhang W, Zhang Y, Wang TD, and Li M
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antineoplastic Agents, Phytogenic therapeutic use, Drug Delivery Systems methods, Epithelial Cell Adhesion Molecule immunology, Gastrointestinal Neoplasms diagnosis, Gastrointestinal Neoplasms pathology, Gene Knockdown Techniques, HT29 Cells, Humans, Ligands, Male, Mice, Mice, Nude, Micelles, Molecular Docking Simulation, Oligopeptides chemistry, Paclitaxel therapeutic use, Peptide Fragments chemistry, Phosphatidylethanolamines chemistry, Polyethylene Glycols chemistry, Protein Binding, Transfection, Wnt Signaling Pathway, Xenograft Model Antitumor Assays, beta Catenin metabolism, Epithelial Cell Adhesion Molecule genetics, Epithelial Cell Adhesion Molecule metabolism, Gastrointestinal Neoplasms metabolism, Gastrointestinal Neoplasms therapy, Oligopeptides metabolism, Peptide Fragments metabolism
- Abstract
Tumor targeting agents are being developed for early tumor detection and therapeutics. We previously identified the peptide SNFYMPL (SNF*) and demonstrated its specific binding to human esophageal specimens of high-grade dysplasia (HGD) and adenocarcinoma with imaging ex vivo. Here, we aim to identify the target for this peptide and investigate its potential applications in imaging and drug delivery. With SNF* conjugated affinity chromatography, mass spectrum, Western blot, enzyme-linked immunosorbent assay (ELISA), and molecular docking, we found that the epithelial cell adhesion molecule (EpCAM) was the potential target of SNF*. Next, we showed that FITC-labeled SNF* (SNF*-FITC) colocalized with EpCAM antibody on the surface of esophageal adenocarcinoma cells OE33, and SNF*-FITC binding patterns significantly changed after EpCAM knockdown or exogenous EpCAM transfection. With the data from TCGA, we demonstrated that EpCAM was overexpressed in 17 types of cancers. Using colon and gastric adenocarcinoma cells and tissues as examples, we found that SNF*-FITC bound in a pattern was colocalized with EpCAM antibody, and the SNF* binding did not upregulate the EpCAM downstream Wnt signals. Subsequently, we conjugated SNF* with our previously constructed poly(histidine)-PEG/DSPE copolymer micelles. SNF* labeling significantly improved the micelle binding with colon and gastric adenocarcinoma cells in vitro, and enhanced the antitumor effects and decreased the toxicities of the micelles in vivo. In conclusion, we identified and validated SNF* as a specific peptide for EpCAM. The future potential use of SNF* peptide in multiple tumor surveillance and tumor-targeted therapeutics was demonstrated.
- Published
- 2019
- Full Text
- View/download PDF
12. Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage.
- Author
-
Ferrer-Torres D, Nancarrow DJ, Steinberg H, Wang Z, Kuick R, Weh KM, Mills RE, Ray D, Ray P, Lin J, Chang AC, Reddy RM, Orringer MB, Canto MI, Shaheen NJ, Kresty LA, Chak A, Wang TD, Rubenstein JH, and Beer DG
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma ethnology, Adenocarcinoma pathology, Animals, Barrett Esophagus enzymology, Barrett Esophagus ethnology, Barrett Esophagus pathology, Disease Models, Animal, Esophageal Mucosa pathology, Esophageal Neoplasms enzymology, Esophageal Neoplasms ethnology, Esophageal Neoplasms pathology, Female, Gastroesophageal Reflux enzymology, Gastroesophageal Reflux ethnology, Gastroesophageal Reflux pathology, Glutathione Transferase metabolism, HeLa Cells, Histones metabolism, Humans, Incidence, Male, Middle Aged, Phosphoproteins metabolism, Phosphorylation, Protective Factors, Rats, Sprague-Dawley, Risk Factors, United States epidemiology, Up-Regulation, Adenocarcinoma genetics, Black or African American genetics, Barrett Esophagus genetics, DNA Damage, Esophageal Mucosa enzymology, Esophageal Neoplasms genetics, Gastroesophageal Reflux genetics, Glutathione Transferase genetics, White People genetics
- Abstract
Background & Aims: African American and European American individuals have a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal adenocarcinoma (EAC) disproportionately affects European American individuals. We investigated whether the esophageal squamous mucosa of African American individuals has features that protect against GERD-induced damage, compared with European American individuals., Methods: We performed transcriptional profile analysis of esophageal squamous mucosa tissues from 20 African American and 20 European American individuals (24 with no disease and 16 with Barrett's esophagus and/or EAC). We confirmed our findings in a cohort of 56 patients and analyzed DNA samples from patients to identify associated variants. Observations were validated using matched genomic sequence and expression data from lymphoblasts from the 1000 Genomes Project. A panel of esophageal samples from African American and European American subjects was used to confirm allele-related differences in protein levels. The esophageal squamous-derived cell line Het-1A and a rat esophagogastroduodenal anastomosis model for reflux-generated esophageal damage were used to investigate the effects of the DNA-damaging agent cumene-hydroperoxide (cum-OOH) and a chemopreventive cranberry proanthocyanidin (C-PAC) extract, respectively, on levels of protein and messenger RNA (mRNA)., Results: We found significantly higher levels of glutathione S-transferase theta 2 (GSTT2) mRNA in squamous mucosa from African American compared with European American individuals and associated these with variants within the GSTT2 locus in African American individuals. We confirmed that 2 previously identified genomic variants at the GSTT2 locus, a 37-kb deletion and a 17-bp promoter duplication, reduce expression of GSTT2 in tissues from European American individuals. The nonduplicated 17-bp promoter was more common in tissue samples from populations of African descendant. GSTT2 protected Het-1A esophageal squamous cells from cum-OOH-induced DNA damage. Addition of C-PAC increased GSTT2 expression in Het-1A cells incubated with cum-OOH and in rats with reflux-induced esophageal damage. C-PAC also reduced levels of DNA damage in reflux-exposed rat esophagi, as observed by reduced levels of phospho-H2A histone family member X., Conclusions: We found GSTT2 to protect esophageal squamous cells against DNA damage from genotoxic stress and that GSTT2 expression can be induced by C-PAC. Increased levels of GSTT2 in esophageal tissues of African American individuals might protect them from GERD-induced damage and contribute to the low incidence of EAC in this population., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
13. Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
- Author
-
Heiden BT, Patel N, Nancarrow DJ, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, and Reddy RM
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma metabolism, Aged, Aged, 80 and over, Esophageal Neoplasms genetics, Esophageal Neoplasms metabolism, Female, Gene Ontology, Glycolysis, Humans, Male, Middle Aged, Adenocarcinoma diagnostic imaging, Esophageal Neoplasms diagnostic imaging, Fluorodeoxyglucose F18, Organic Cation Transport Proteins genetics, Positron-Emission Tomography methods, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Background: 18F-fluorodeoxyglucose positron emission tomography is an imaging modality critical to the diagnosis and staging of esophageal cancer. Despite this, the genetic abnormalities associated with increased 18F-fluorodeoxyglucose (FDG)-maximum standardized uptake value (SUVmax) have not been previously explored in esophageal adenocarcinoma., Materials and Methods: Treatment-naïve patients, for whom frozen tissue and 18F-fluorodeoxyglucose positron emission tomography data were available, undergoing esophagectomy from 2003 to 2012, were identified. Primary tumor FDG-uptake (SUVmax) was quantified as low (<5), moderate, or high (>10). Genome-wide expression analyses (e.g., microarray) were used to examine gene expression differences associated with FDG-uptake., Results: Eighteen patients with stored positron emission tomography data and tissue were reviewed. Overall survival was similar between patients with high (n = 9) and low (n = 6) FDG-uptake tumors (P = 0.71). Differences in gene expression between tumors with high and low FDG-uptake included enriched expression of various matrix metalloproteinases, extracellular-matrix components, oncogenic signaling members, and PD-L1 (fold-change>2.0, P < 0.05) among the high-FDG tumors. Glycolytic gene expression and pathway involvement were similar between the high- and low-FDG tumor subsets (P = 0.126). Gene ontology analysis of the most differentially expressed genes demonstrated significant upregulation of gene sets associated with extracellular matrix organization and vascular development (P < 0.005). Gene set enrichment analysis further demonstrated associations between FDG-uptake intensity and canonical oncogenic processes, including hypoxia, angiogenesis, KRAS signaling, and epithelial-to-mesenchymal transition (P < 0.001). Interestingly, KRAS expression did not predict worse survival in a larger cohort (n = 104) of esophageal adenocarcinomas (P = 0.64)., Conclusions: These results suggest that elevated FDG-uptake is associated with a variety of oncogenic alterations in operable esophageal adenocarcinoma. These pathways present potential therapeutic targets among tumors exhibiting high FDG-uptake., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
14. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
- Author
-
Feingold PL, Surman DR, Brown K, Xu Y, McDuffie LA, Shukla V, Reardon ES, Crooks DR, Trepel JB, Lee S, Lee MJ, Gao S, Xi S, McLoughlin KC, Diggs LP, Beer DG, Nancarrow DJ, Neckers LM, Davis JL, Hoang CD, Hernandez JM, Schrump DS, and Ripley RT
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma metabolism, Animals, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Apoptosis genetics, Carrier Proteins metabolism, Cell Line, Tumor, Cisplatin administration & dosage, Esophageal Neoplasms genetics, Esophageal Neoplasms metabolism, Female, Gene Expression Regulation, Neoplastic drug effects, Histone Deacetylase Inhibitors pharmacology, Humans, Mice, Nude, Transcriptional Activation drug effects, Adenocarcinoma drug therapy, Apoptosis drug effects, Benzamides pharmacology, Carrier Proteins genetics, DNA Damage, Esophageal Neoplasms drug therapy, Pyridines pharmacology, Xenograft Model Antitumor Assays
- Abstract
In 2017, an estimated 17,000 individuals were diagnosed with esophageal adenocarcinoma (EAC), and less than 20% will survive 5 years. Positron emission tomography avidity is indicative of high glucose utilization and is nearly universal in EAC. TXNIP blocks glucose uptake and exhibits proapoptotic functions. Higher expression in EAC has been associated with improved disease-specific survival, lack of lymph node involvement, reduced perineural invasion, and increased tumor differentiation. We hypothesized that TXNIP may act as a tumor suppressor that sensitizes EAC cells to standard chemotherapeutics. EAC cell lines and a Barrett epithelial cell line were used. qRT-PCR, immunoblot, and immunofluorescence techniques evaluated gene expression. TXNIP was stably overexpressed or knocked down using lentiviral RNA transduction techniques. Murine xenograft methods examined growth following overexpression of TXNIP. Apoptosis and DNA damage were measured by annexin V and γH2AX assays. Activation of the intrinsic apoptosis was quantitated with green fluorescence protein-caspase 3 reporter assay. In cultured cells and an esophageal tissue array, TXNIP expression was higher in Barrett epithelia and normal tissue compared with EAC. Constitutive overexpression of TXNIP decreased proliferation, clonogenicity, and tumor xenograft growth. TXNIP overexpression increased, whereas knockdown abrogated, DNA damage and apoptosis following cisplatin treatment. An HDAC inhibitor, entinostat (currently in clinical trials), upregulated TXNIP and synergistically increased cisplatin-mediated DNA damage and apoptosis. TXNIP is a tumor suppressor that is downregulated in EACC. Its reexpression dramatically sensitizes these cells to cisplatin. Our findings support phase I/II evaluation of "priming" strategies to enhance the efficacy of conventional chemotherapeutics in EAC. Mol Cancer Ther; 17(9); 2013-23. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
15. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas.
- Author
-
Ferrer-Torres D, Nancarrow DJ, Kuick R, Thomas DG, Nadal E, Lin J, Chang AC, Reddy RM, Orringer MB, Taylor JM, Wang TD, and Beer DG
- Subjects
- Aged, Cadherins genetics, Claudin-3 genetics, Female, Gene Expression Profiling methods, Humans, Intercellular Adhesion Molecule-1 genetics, Kaplan-Meier Estimate, Male, Multivariate Analysis, Mutation, Adenocarcinoma genetics, Barrett Esophagus genetics, Esophageal Neoplasms genetics, Esophagogastric Junction metabolism, Genomics methods
- Abstract
The current high mortality rate of esophageal adenocarcinoma (EAC) reflects frequent presentation at an advanced stage. Recent efforts utilizing fluorescent peptides have identified overexpressed cell surface targets for endoscopic detection of early stage Barrett's-derived EAC. Unfortunately, 30% of EAC patients present with gastroesophageal junction adenocarcinomas (GEJAC) and lack premalignant Barrett's metaplasia, limiting this early detection strategy. We compared mRNA profiles from 52 EACs (tubular EAC; tEAC) collected above the gastroesophageal junction with 70 GEJACs, 8 normal esophageal and 5 normal gastric mucosa samples. We also analyzed our previously published whole-exome sequencing data in a large cohort of these tumors. Principal component analysis, hierarchical clustering and survival-based analyses demonstrated that GEJAC and tEAC were highly similar, with only modest differences in expression and mutation profiles. The combined expression cohort allowed identification of 49 genes coding cell surface targets overexpressed in both GEJAC and tEAC. We confirmed that three of these candidates (CDH11, ICAM1 and CLDN3) were overexpressed in tumors when compared to normal esophagus, normal gastric and non-dysplastic Barrett's, and localized to the surface of tumor cells. Molecular profiling of tEAC and GEJAC tumors indicated extensive similarity and related molecular processes. Identified genes that encode cell surface proteins overexpressed in both Barrett's-derived EAC and those that arise without Barrett's metaplasia will allow simultaneous detection strategies.
- Published
- 2016
- Full Text
- View/download PDF
16. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
- Author
-
Myers AL, Lin L, Nancarrow DJ, Wang Z, Ferrer-Torres D, Thomas DG, Orringer MB, Lin J, Reddy RM, Beer DG, and Chang AC
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma metabolism, Adult, Aged, Aged, 80 and over, Antineoplastic Agents pharmacology, Cell Line, Tumor, Cell Movement drug effects, Cell Movement genetics, Cell Proliferation drug effects, Cell Proliferation genetics, Cisplatin pharmacology, Culture Media, Serum-Free pharmacology, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, Esophageal Neoplasms drug therapy, Esophageal Neoplasms metabolism, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Immunoblotting, Insulin-Like Growth Factor Binding Protein 2 metabolism, Insulin-Like Growth Factor I pharmacology, MAP Kinase Signaling System drug effects, Male, Middle Aged, RNA Interference, Reverse Transcriptase Polymerase Chain Reaction, Survival Analysis, Adenocarcinoma genetics, Esophageal Neoplasms genetics, Gene Expression Profiling methods, Insulin-Like Growth Factor Binding Protein 2 genetics
- Abstract
Esophageal adenocarcinoma (EAC) patients commonly present with advanced stage disease and demonstrate resistance to therapy, with response rates below 40%. Understanding the molecular mechanisms of resistance is crucial for improvement of clinical outcomes. IGFBP2 is a member of the IGFBP family of proteins that has been reported to modulate both IGF and integrin signaling and is a mediator of cell growth, invasion and resistance in other tumor types. In this study, high IGFBP2 expression was observed in a subset of primary EACs and was found to be significantly higher in patients with shorter disease-free intervals as well as in treatment-resistant EACs as compared to chemonaive EACs. Modulation of IGFBP2 expression in EAC cell lines promoted cell proliferation, migration and invasion, implicating a role in the metastatic potential of these cells. Additionally, knockdown of IGFBP2 sensitized EAC cells to cisplatin in a serum-dependent manner. Further in vitro exploration into this chemosensitization implicated both the AKT and ERK pathways. Silencing of IGFBP2 enhanced IGF1-induced immediate activation of AKT and reduced cisplatin-induced ERK activation. Addition of MEK1/2 (selumetinib or trametinib) or AKT (AKT Inhibitor VIII) inhibitors enhanced siIGFBP2-induced sensitization of EAC cells to cisplatin. These results suggest that targeted inhibition of IGFBP2 alone or together with either the MAPK or PI3K/AKT signaling pathway in IGFBP2-overexpressing EAC tumors may be an effective approach for sensitizing resistant EACs to standard neoadjuvant chemotherapy.
- Published
- 2015
- Full Text
- View/download PDF
17. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.
- Author
-
Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG, and Lin L
- Subjects
- Adenocarcinoma genetics, Cadherins biosynthesis, Cell Adhesion physiology, Cell Line, Tumor, Cell Movement physiology, Cell Proliferation physiology, Esophageal Neoplasms genetics, Humans, Incidence, Neoplasm Invasiveness, Osteopontin biosynthesis, Osteopontin genetics, Protein Isoforms, Signal Transduction, Tissue Array Analysis, Vimentin biosynthesis, Adenocarcinoma metabolism, Adenocarcinoma pathology, Esophageal Neoplasms metabolism, Esophageal Neoplasms pathology, Osteopontin metabolism
- Abstract
Esophageal adenocarcinoma (EAC) is often diagnosed at an advanced stage, thus understanding the molecular basis for EAC invasion and metastasis is critical. Here we report that SPP1/OPN was highly overexpressed in primary EACs and intracellularly localized to tumor cells. We further demonstrate that all known OPN isoforms (OPNa, b, c, 4 and 5) were frequently co-overexpressed in primary EACs. Distinct pro-invasion and dissemination phenotypes of isoform-specific OPNb and OPNc stable transfectants were observed. Expression of OPNb significantly enhanced cell migration and adhesion to laminin. In contrast, OPNc cells showed significantly decreased cell migration yet increased cell detachment. Enhanced invasion, both in vitro and in vivo, was observed for OPNb- but not OPNc-expressing cells. Inhibition of RGD integrins, one family of OPN receptors, attenuated OPNb cell migration, abrogated OPNb cell adhesion and significantly reduced OPNb cell clonogenic survival but did not affect OPNc phenotypes, indicating that OPNb but not OPNc acts through integrin-dependent signaling. Differential expression of vimentin, E-cadherin and β-catenin in OPN stable cells may account for the variation in cell adhesion and detachment between these isoforms. We conclude that while all OPN isoforms are frequently co-overexpressed in primary EACs, isoforms OPNb and OPNc enhance invasion and dissemination through collective yet distinct mechanisms.
- Published
- 2015
- Full Text
- View/download PDF
18. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability.
- Author
-
Bond CE, Nancarrow DJ, Wockner LF, Wallace L, Montgomery GW, Leggett BA, and Whitehall VL
- Subjects
- Aged, Cohort Studies, DNA Copy Number Variations genetics, Female, Genome, Human genetics, Humans, Male, Sequence Deletion, Amino Acid Substitution genetics, Chromosomal Instability genetics, Colorectal Neoplasms genetics, Microsatellite Instability, Mutation genetics, Proto-Oncogene Proteins B-raf genetics
- Abstract
The BRAF (V600E) mutation in colorectal cancers that are microsatellite stable (MSS) confers a poor patient prognosis, whereas BRAF mutant microsatellite-unstable (MSI) colorectal cancers have an excellent prognosis. BRAF wild type cancers are typically MSS and display chromosomal instability (CIN). CIN has not been extensively studied on a genome-wide basis in relation to BRAF mutational status in colorectal cancer. BRAF mutant/MSS (BRAFmut/MSS) cancers (n = 33) and BRAF mutant/MSI (BRAFmut/MSI) cancers (n = 30) were compared for presence of copy number aberrations (CNAs) indicative of CIN, with BRAF wild type/MSS (BRAFwt/MSS) cancers (n = 18) using Illumina CytoSNP-12 arrays. BRAFmut/MSS and BRAFwt/MSS cancers showed comparable numbers of CNAs/cancer at 32.8 and 29.8 respectively. However, there were differences in patterns of CNA length between MSS cohorts, with BRAFmut/MSS cancers having significantly greater proportions of focal CNAs compared to BRAFwt/MSS cancers (p<0.0001); whereas whole chromosomal arm CNAs were more common in BRAFwt/MSS cancers (p<0.0001). This related to a reduced average CNA length in BRAFmut/MSS compared to BRAFwt/MSS cancers (20.7 Mb vs 33.4 Mb;p<0.0001); and a smaller average percent of CIN affected genomes in BRAFmut/MSS compared to BRAFwt/MSS cancers (23.9% vs 34.9% respectively). BRAFmut/MSI cancers were confirmed to have low CNA rates (5.4/cancer) and minimal CIN-affected genomes (average of 4.5%) compared to MSS cohorts (p<0.0001). BRAFmut/MSS cancers had more frequent deletion CNAs compared to BRAFwt/MSS cancers on 6p and 17q at loci not typically correlated with colorectal cancer, and greater amplification CNAs on 8q and 18q compared to BRAFwt/MSS cancers. These results indicate that comparable rates of CIN occur between MSS subgroups, however significant differences in their patterns of instability exist, with BRAFmut/MSS cancers showing a 'focal pattern' and BRAFwt/MSS cancers having a 'whole arm pattern' of CIN. This and the genomic loci more frequently affected in BRAFmut/MSS cancers provides further evidence of the biological distinctions of this important cancer subgroup.
- Published
- 2014
- Full Text
- View/download PDF
19. Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.
- Author
-
Dutton-Regester K, Aoude LG, Nancarrow DJ, Stark MS, O'Connor L, Lanagan C, Pupo GM, Tembe V, Carter CD, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, and Hayward NK
- Subjects
- Cell Line, Tumor, Gene Amplification, Gene Deletion, Homozygote, Humans, Mutation, Neoplasm Metastasis, Neoplasm Staging, Genes, Tumor Suppressor, Melanoma genetics, Melanoma pathology, Proteins genetics
- Abstract
High density SNP arrays can be used to identify DNA copy number changes in tumors such as homozygous deletions of tumor suppressor genes and focal amplifications of oncogenes. Illumina Human CNV370 Bead chip arrays were used to assess the genome for unbalanced chromosomal events occurring in 39 cell lines derived from stage III metastatic melanomas. A number of genes previously recognized to have an important role in the development and progression of melanoma were identified including homozygous deletions of CDKN2A (13 of 39 samples), CDKN2B (10 of 39), PTEN (3 of 39), PTPRD (3 of 39), TP53 (1 of 39), and amplifications of CCND1 (2 of 39), MITF (2 of 39), MDM2 (1 of 39), and NRAS (1 of 39). In addition, a number of focal homozygous deletions potentially targeting novel melanoma tumor suppressor genes were identified. Because of their likely functional significance for melanoma progression, FAS, CH25H, BMPR1A, ACTA2, and TFG were investigated in a larger cohort of melanomas through sequencing. Nonsynonymous mutations were identified in BMPR1A (1 of 43), ACTA2 (3 of 43), and TFG (5 of 103). A number of potentially important mutation events occurred in TFG including the identification of a mini mutation "hotspot" at amino acid residue 380 (P380S and P380L) and the presence of multiple mutations in two melanomas. Mutations in TFG may have important clinical relevance for current therapeutic strategies to treat metastatic melanoma., (Copyright © 2012 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
20. Barrett's esophagus.
- Author
-
Phillips WA, Lord RV, Nancarrow DJ, Watson DI, and Whiteman DC
- Subjects
- Biomarkers, Tumor analysis, Disease Progression, Esophagus pathology, Humans, Metaplasia, Prevalence, Risk Assessment, Risk Factors, Treatment Outcome, Adenocarcinoma diagnosis, Adenocarcinoma epidemiology, Adenocarcinoma therapy, Barrett Esophagus diagnosis, Barrett Esophagus epidemiology, Barrett Esophagus therapy, Esophageal Neoplasms diagnosis, Esophageal Neoplasms epidemiology, Esophageal Neoplasms therapy, Precancerous Conditions diagnosis, Precancerous Conditions epidemiology, Precancerous Conditions therapy
- Abstract
Barrett's esophagus is an acquired metaplastic abnormality in which the normal stratified squamous epithelium lining of the esophagus is replaced by an intestinal-like columnar epithelium. While in itself a benign and asymptomatic disorder, the clinical importance of this relatively common condition relates to its role as a precursor lesion to esophageal adenocarcinoma, the incidence of which has dramatically increased in Western populations in recent years. Although known to arise as a consequence of chronic gastroesophageal reflux, the cellular and molecular mechanisms underlying development Barrett's esophagus and its progression to cancer remain unclear., (© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
21. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
- Author
-
Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, Tyagi S, Hayward NK, and Whiteman DC
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma pathology, Adolescent, Adult, Aged, Aged, 80 and over, Barrett Esophagus metabolism, Barrett Esophagus pathology, Biomarkers, Tumor metabolism, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Case-Control Studies, Cell Proliferation, Esophageal Neoplasms metabolism, Esophageal Neoplasms pathology, Esophagus pathology, Female, Genome, Human, Humans, Male, Middle Aged, Mucous Membrane pathology, Oligonucleotide Array Sequence Analysis, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Support Vector Machine, Young Adult, Adenocarcinoma genetics, Barrett Esophagus genetics, Biomarkers, Tumor genetics, Esophageal Neoplasms genetics, Esophagus metabolism, Gene Expression Profiling, Mucous Membrane metabolism
- Abstract
Esophageal adenocarcinoma (EAC) has become a major concern in Western countries due to rapid rises in incidence coupled with very poor survival rates. One of the key risk factors for the development of this cancer is the presence of Barrett's esophagus (BE), which is believed to form in response to repeated gastro-esophageal reflux. In this study we performed comparative, genome-wide expression profiling (using Illumina whole-genome Beadarrays) on total RNA extracted from esophageal biopsy tissues from individuals with EAC, BE (in the absence of EAC) and those with normal squamous epithelium. We combined these data with publically accessible raw data from three similar studies to investigate key gene and ontology differences between these three tissue states. The results support the deduction that BE is a tissue with enhanced glycoprotein synthesis machinery (DPP4, ATP2A3, AGR2) designed to provide strong mucosal defenses aimed at resisting gastro-esophageal reflux. EAC exhibits the enhanced extracellular matrix remodeling (collagens, IGFBP7, PLAU) effects expected in an aggressive form of cancer, as well as evidence of reduced expression of genes associated with mucosal (MUC6, CA2, TFF1) and xenobiotic (AKR1C2, AKR1B10) defenses. When our results are compared to previous whole-genome expression profiling studies keratin, mucin, annexin and trefoil factor gene groups are the most frequently represented differentially expressed gene families. Eleven genes identified here are also represented in at least 3 other profiling studies. We used these genes to discriminate between squamous epithelium, BE and EAC within the two largest cohorts using a support vector machine leave one out cross validation (LOOCV) analysis. While this method was satisfactory for discriminating squamous epithelium and BE, it demonstrates the need for more detailed investigations into profiling changes between BE and EAC.
- Published
- 2011
- Full Text
- View/download PDF
22. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.
- Author
-
Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, and Hayward NK
- Subjects
- Animals, Cell Line, Tumor, CpG Islands genetics, Humans, Infant, Newborn, Oligonucleotide Array Sequence Analysis, Promoter Regions, Genetic genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Skin Neoplasms genetics, Skin Neoplasms pathology, Thrombospondin 1 deficiency, Thrombospondin 1 genetics, Tumor Necrosis Factor Decoy Receptors deficiency, Tumor Necrosis Factor Decoy Receptors genetics, Ubiquitin Thiolesterase deficiency, Ubiquitin Thiolesterase genetics, Collagen Type I genetics, DNA Methylation genetics, Gene Silencing, Genes, Tumor Suppressor, Melanoma genetics, Melanoma pathology
- Abstract
Epigenetic regulation of tumor suppressor genes (TSGs) has been shown to play a central role in melanomagenesis. By integrating gene expression and methylation array analysis we identified novel candidate genes frequently methylated in melanoma. We validated the methylation status of the most promising genes using highly sensitive Sequenom Epityper assays in a large panel of melanoma cell lines and resected melanomas, and compared the findings with those from cultured melanocytes. We found transcript levels of UCHL1, COL1A2, THBS1 and TNFRSF10D were inversely correlated with promoter methylation. For THBS1 and UCHL1 the effect of this methylation on expression was confirmed at the protein level. Identification of these candidate TSGs and future research designed to understand how their silencing is related to melanoma development will increase our understanding of the etiology of this cancer and may provide tools for its early diagnosis.
- Published
- 2011
- Full Text
- View/download PDF
23. webFOG: A web tool to map genomic features onto genes.
- Author
-
Tyagi S, Stark MS, Hayward NK, Whiteman DC, and Nancarrow DJ
- Subjects
- CpG Islands, Humans, MicroRNAs genetics, Promoter Regions, Genetic, Chromosome Mapping methods, Genome, Human genetics, High-Throughput Screening Assays, Internet, Sequence Alignment methods, Software
- Abstract
A large number of new genomic features are being discovered using high throughput techniques. The next challenge is to automatically map them to the reference genome for further analysis and functional annotation. We have developed a tool that can be used to map important genomic features to the latest version of the human genome and also to annotate new features. These genomic features could be of many different source types, including miRNAs, microarray primers or probes, Chip-on-Chip data, CpG islands and SNPs to name a few. A standalone version and web interface for the tool can be accessed through: http://populationhealth.qimr.edu.au/cgi-bin/webFOG/index.cgi. The project details and source code is also available at http://www.bioinformatics.org/webfog., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
24. High-risk human papillomavirus in esophageal squamous cell carcinoma.
- Author
-
Antonsson A, Nancarrow DJ, Brown IS, Green AC, Drew PA, Watson DI, Hayward NK, and Whiteman DC
- Subjects
- Adult, Age Factors, Aged, Australia epidemiology, Body Mass Index, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Case-Control Studies, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Female, Humans, Life Style, Male, Middle Aged, Neoplasm Staging, Risk Factors, Survival Analysis, Carcinoma, Squamous Cell virology, DNA, Viral analysis, Esophageal Neoplasms virology, Papillomaviridae classification, Papillomavirus Infections complications
- Abstract
Background: Although most cases of esophageal squamous cell carcinoma (ESCC) in western populations have been attributed to high levels of exposure to tobacco and alcohol, infectious agents have been postulated as possible causes, particularly human papillomavirus (HPV)., Methods: To explore this issue, we analyzed HPV DNA prevalence and HPV types together with lifestyle factors, in relation to tumor stage and survival in a low-incidence population. Archived tumor samples from a nationwide cohort of 222 ESCC patients were tested for the presence of HPV DNA by PCR; positive samples were sequenced to determine HPV type, and p16(INK4a) status was assessed by immunohistochemistry., Results: Of 222 ESCC patients, 8 tested HPV positive (prevalence, 3.6%; 95% confidence interval, 1.1-6.1%), of which 6 were HPV-16 positive and 2 were HPV-35 positive. Four of the eight HPV-positive tumors overexpressed p16(INK4a). None of 55 normal esophageal tissue samples from healthy participants had any detectable HPV. Although the numbers were low, it seemed that patients with HPV-positive ESCC tumors were younger than those with HPV-negative tumors (mean age, 60.8 versus 65.3 years, P = 0.18) and had higher body mass index (BMI) throughout life (mean current BMI of 25.1 for HPV positive, 22.2 for HPV negative, P = 0.08; mean BMI at 20 years of 25.8 for HPV positive, 22.1 for HPV negative, P = 0.003). We found no difference between patients with HPV-positive and HPV-negative tumors with respect to other lifestyle factors., Conclusions: These findings suggest a very low prevalence of HPV DNA in human ESCC., Impact: HPV is very unlikely to be a common cause of ESCC in Australia., ((c)2010 AACR.)
- Published
- 2010
- Full Text
- View/download PDF
25. Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues.
- Author
-
Botelho NK, Schneiders FI, Lord SJ, Freeman AK, Tyagi S, Nancarrow DJ, Hayward NK, Whiteman DC, and Lord RV
- Subjects
- Analysis of Variance, Down-Regulation genetics, Formaldehyde, Genetic Markers, Humans, Paraffin Embedding, Principal Component Analysis, Up-Regulation genetics, Adenocarcinoma genetics, Barrett Esophagus genetics, Esophageal Neoplasms genetics, Gene Expression Profiling methods, Polymerase Chain Reaction methods
- Abstract
Background and Aim: Widespread applicability of tissue-based mRNA expression screening for Barrett esophagus (BE) is likely to require (1) accurate methods for assaying archival formalin-fixed, paraffin-embedded (FFPE) histopathology specimens taken at endoscopy, and (2) validation studies of promising biomarkers in different patient cohorts., Results: 30 genes were significantly differentially expressed by histopathology tissue type. The direction and magnitude of the differences were very similar to those found in previous studies using fresh frozen tissues. Novel upregulated genes were TSPAN8 (also known as CO-029), TSPAN24 (CD151), EGR1 and TCIRG1. Novel downregulated genes were DPYD, TSPAN29 (CD9) and Ets1. Strong associations between histopathology type and gene expression were observed with the overexpressed genes: cyclo-oxygenase-2 (COX-2), for which histopathology type explained 77.7% of the variation in expression, TSPAN1 (73.5%), TSPAN8 (62.9%), SPARC (62.1%), MMP7 (50.8%); and the under-expressed genes ADH7 (53.7%), APC (58.2%), RAR-gamma (51.3%)., Methods: mRNA was isolated from 54 FFPE small endoscopic biopsies from patients with Barrett intestinal metaplasia (BE), esophageal adenocarcinoma (EAC), or control patients with a normal squamous-lined esophagus. Multiplexed tandem PCR (MT-PCR) was used to quantitate 50 selected candidate genes for BE and control genes in duplicate. Principal component analysis (PCA) was conducted to explore the presence of global differences in gene expression profiles. One-way analysis of variance (ANOVA) of the transformed data was used to identify genes that were differentially expressed between different histological subtypes. Differentially expressed genes with a fold change of ≥2 (upregulated) or ≤-2 (downregulated) are reported with the p value for each comparison (EAC vs. normal, EAC vs. BE and BE vs. normal). The Benjamini-Hochberg method was used to control the false discovery rate at 0.01 for all comparisons., Conclusions: Alterations in expression of select genes are strongly associated with BE or EAC or both. This study's findings for many highly differentially expressed genes are very similar to those previously reported, suggesting that these genes should be tested further in longitudinal studies for their potential role as biomarkers of progression to more advanced Barrett disease.
- Published
- 2010
- Full Text
- View/download PDF
26. Characterization of the Melanoma miRNAome by Deep Sequencing.
- Author
-
Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, Parsons PG, Schmidt C, Sturm RA, and Hayward NK
- Subjects
- Cluster Analysis, Disease Progression, Gene Library, Genome, Humans, Melanocytes cytology, MicroRNAs metabolism, Neoplasm Metastasis, RNA, Untranslated genetics, Reverse Transcriptase Polymerase Chain Reaction, Skin Neoplasms genetics, Melanoma genetics, MicroRNAs genetics, Sequence Analysis, RNA
- Abstract
Background: MicroRNAs (miRNAs) are 18-23 nucleotide non-coding RNAs that regulate gene expression in a sequence specific manner. Little is known about the repertoire and function of miRNAs in melanoma or the melanocytic lineage. We therefore undertook a comprehensive analysis of the miRNAome in a diverse range of pigment cells including: melanoblasts, melanocytes, congenital nevocytes, acral, mucosal, cutaneous and uveal melanoma cells., Methodology/principal Findings: We sequenced 12 small RNA libraries using Illumina's Genome Analyzer II platform. This massively parallel sequencing approach of a diverse set of melanoma and pigment cell libraries revealed a total of 539 known mature and mature-star sequences, along with the prediction of 279 novel miRNA candidates, of which 109 were common to 2 or more libraries and 3 were present in all libraries., Conclusions/significance: Some of the novel candidate miRNAs may be specific to the melanocytic lineage and as such could be used as biomarkers to assist in the early detection of distant metastases by measuring the circulating levels in blood. Follow up studies of the functional roles of these pigment cell miRNAs and the identification of the targets should shed further light on the development and progression of melanoma.
- Published
- 2010
- Full Text
- View/download PDF
27. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India.
- Author
-
Holliday EG, Nyholt DR, Tirupati S, John S, Ramachandran P, Ramamurti M, Ramadoss AJ, Jeyagurunathan A, Kottiswaran S, Smith HJ, Filippich C, Nertney DA, Nancarrow DJ, Hayward NK, Watkins WS, Jorde LB, Thara R, and Mowry BJ
- Subjects
- Adult, Alleles, Consanguinity, Cyclic Nucleotide Phosphodiesterases, Type 4 genetics, Female, Genotype, Humans, India, Lod Score, Male, Microsatellite Repeats genetics, Middle Aged, Polymorphism, Single Nucleotide genetics, Schizophrenia diagnosis, Schizophrenia ethnology, Chromosome Mapping, Chromosomes, Human, Pair 1 genetics, Schizophrenia genetics
- Abstract
Objective: The study of ethnically homogeneous populations may help to identify schizophrenia risk loci. The authors conducted a genomewide linkage scan for schizophrenia in an Indian population., Method: Participants were 441 individuals (262 affected probands and siblings) who were recruited primarily from one ethnically homogeneous group, the Tamil Brahmin caste, although individuals from other geographically proximal castes also participated. Genotyping of 124 affected sibling pair pedigrees was performed with 402 short tandem repeat polymorphisms. Linkage analyses were conducted using nonparametric exponential LOD (logarithm of the odds ratio for linkage) scores and parametric heterogeneity LOD scores. Parametric heterogeneity scores were calculated using simple dominant and recessive models, correcting for multiple statistics. The data were examined for evidence of consanguinity. Genomewide significance levels were determined using 10,000 gene dropping simulations., Results: These findings revealed genomewide significant linkage to chromosome 1p31.1, through the use of both exponential and heterogeneity LOD scores, incorporating correction for multiple statistics and mild consanguinity. The estimated sibling recurrence risk associated with this putative locus was 1.95. Analysis for heterogeneity LOD scores also detected suggestive linkage to chromosomes 13q22.1 and 16q12.2. Using 117 tag single nucleotide polymorphisms (SNPs), family-based association analyses of phosphodiesterase 4B (PDE4B), the closest schizophrenia candidate gene, detected no convincing evidence of association, suggesting that the chromosome 1 peak represents a novel risk locus., Conclusions: This is the first study-to the authors' knowledge-to report significant linkage of schizophrenia to chromosome 1p31.1. Further investigation of this chromosome region in diverse populations is warranted to identify underlying sequence variants.
- Published
- 2009
- Full Text
- View/download PDF
28. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
- Author
-
Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, Devitt PG, Jamieson GG, and Drew PA
- Subjects
- Adenocarcinoma pathology, Barrett Esophagus pathology, Cell Line, Tumor, Esophageal Neoplasms pathology, Gene Expression Profiling, Humans, Adenocarcinoma genetics, Barrett Esophagus genetics, DNA Methylation, Esophageal Neoplasms genetics
- Abstract
Background: Barrett's esophagus (BE) is the metaplastic replacement of squamous with columnar epithelium in the esophagus, as a result of reflux. It is the major risk factor for the development of esophageal adenocarcinoma (EAC). Methylation of CpG dinucleotides of normally unmethylated genes is associated with silencing of their expression, and is common in EAC. This study was designed to determine at what stage, in the progression from BE to EAC, methylation of key genes occurs., Results: We examined nine genes (APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2), frequently methylated in multiple cancer types, in a panel of squamous (19 biopsies from patients without BE or EAC, 16 from patients with BE, 21 from patients with EAC), BE (40 metaplastic, seven high grade dysplastic) and 37 EAC tissues. The methylation frequency, the percentage of samples that had any extent of methylation, for each of the nine genes in the EAC (95%, 59%, 76%, 57%, 70%, 73%, 95%, 74% and 83% respectively) was significantly higher than in any of the squamous groups. The methylation frequency for each of the nine genes in the metaplastic BE (95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively) was significantly higher than in the squamous samples except for CDKN2A and RBP1. The methylation frequency did not differ between BE and EAC samples, except for CDKN2A and RUNX3 which were significantly higher in EAC. The methylation extent was an estimate of both the number of methylated alleles and the density of methylation on these alleles. This was significantly greater in EAC than in metaplastic BE for all genes except APC, MGMT and TIMP3. There was no significant difference in methylation extent for any gene between high grade dysplastic BE and EAC., Conclusion: We found significant methylation in metaplastic BE, which for seven of the nine genes studied did not differ in frequency from that found in EAC. This is also the first report of gene silencing by methylation of ID4 in BE or EAC. This study suggests that metaplastic BE is a highly abnormal tissue, more similar to cancer tissue than to normal epithelium.
- Published
- 2008
- Full Text
- View/download PDF
29. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays.
- Author
-
Nancarrow DJ, Handoko HY, Smithers BM, Gotley DC, Drew PA, Watson DI, Clouston AD, Hayward NK, and Whiteman DC
- Subjects
- Chromosome Mapping, Gene Expression Profiling, Humans, Oligonucleotide Array Sequence Analysis, Adenocarcinoma genetics, Esophageal Neoplasms genetics, Genome, Polymorphism, Single Nucleotide
- Abstract
We applied whole-genome single-nucleotide polymorphism arrays to define a comprehensive genetic profile of 23 esophageal adenocarcinoma (EAC) primary tumor biopsies based on loss of heterozygosity (LOH) and DNA copy number changes. Alterations were common, averaging 97 (range, 23-208) per tumor. LOH and gains averaged 33 (range, 3-83) and 31 (range, 11-73) per tumor, respectively. Copy neutral LOH events averaged 27 (range, 7-57) per EAC. We noted 126 homozygous deletions (HD) across the EAC panel (range, 0-11 in individual tumors). Frequent HDs within FHIT (17 of 23), WWOX (8 of 23), and DMD (6 of 23) suggest a role for common fragile sites or genomic instability in EAC etiology. HDs were also noted for known tumor suppressor genes (TSG), including CDKN2A, CDKN2B, SMAD4, and GALR1, and identified PDE4D and MGC48628 as potentially novel TSGs. All tumors showed LOH for most of chromosome 17p, suggesting that TSGs other than TP53 may be targeted. Frequent gains were noted around MYC (13 of 23), BCL9 (12 of 23), CTAGE1 (14 of 23), and ZNF217 (12 of 23). Thus, we have confirmed previous reports indicating frequent changes to FHIT, CDKN2A, TP53, and MYC in EAC and identified additional genes of interest. Meta-analysis of previous genome-wide EAC studies together with the data presented here highlighted consistent regions of gain on 8q, 18q, and 20q and multiple LOH regions on 4q, 5q, 17p, and 18q, suggesting that more than one gene may be targeted on each of these chromosome arms. The focal gains and deletions documented here are a step toward identifying the key genes involved in EAC development.
- Published
- 2008
- Full Text
- View/download PDF
30. SiDCoN: a tool to aid scoring of DNA copy number changes in SNP chip data.
- Author
-
Nancarrow DJ, Handoko HY, Stark MS, Whiteman DC, and Hayward NK
- Subjects
- Alleles, Cell Line, Tumor, DNA Mutational Analysis, Data Interpretation, Statistical, Gene Deletion, Genomics, Genotype, Homozygote, Humans, Models, Genetic, Software, Computational Biology methods, DNA chemistry, Oligonucleotide Array Sequence Analysis instrumentation, Oligonucleotide Array Sequence Analysis methods, Polymorphism, Single Nucleotide
- Abstract
The recent application of genome-wide, single nucleotide polymorphism (SNP) microarrays to investigate DNA copy number aberrations in cancer has provided unparalleled sensitivity for identifying genomic changes. In some instances the complexity of these changes makes them difficult to interpret, particularly when tumour samples are contaminated with normal (stromal) tissue. Current automated scoring algorithms require considerable manual data checking and correction, especially when assessing uncultured tumour specimens. To address these limitations we have developed a visual tool to aid in the analysis of DNA copy number data. Simulated DNA Copy Number (SiDCoN) is a spreadsheet-based application designed to simulate the appearance of B-allele and logR plots for all known types of tumour DNA copy number changes, in the presence or absence of stromal contamination. The system allows the user to determine the level of stromal contamination, as well as specify up to 3 different DNA copy number aberrations for up to 5000 data points (representing individual SNPs). This allows users great flexibility to assess simple or complex DNA copy number combinations. We demonstrate how this utility can be used to estimate the level of stromal contamination within tumour samples and its application in deciphering the complex heterogeneous copy number changes we have observed in a series of tumours. We believe this tool will prove useful to others working in the area, both as a training tool, and to aid in the interpretation of complex copy number changes.
- Published
- 2007
- Full Text
- View/download PDF
31. Polymorphisms in the vitamin D receptor and their associations with risk of schizophrenia and selected anthropometric measures.
- Author
-
Handoko HY, Nancarrow DJ, Mowry BJ, and McGrath JJ
- Subjects
- Adult, Female, Genotype, Humans, Male, Polymerase Chain Reaction, Receptors, Calcitriol blood, Risk Factors, Schizophrenia blood, Anthropometry, DNA genetics, Polymorphism, Genetic, Receptors, Calcitriol genetics, Schizophrenia genetics
- Abstract
The association between vitamin D levels and skeletal growth has long been recognized. However, exposure to low levels of vitamin D during early life is also known to alter brain development, and is a candidate risk factor for schizophrenia. This study examines the association between four polymorphisms in the vitamin D receptor (VDR) and 1) risk of schizophrenia, and 2) three anthropometric variables (height, head size, and head shape). Four single-nucleotide polymorphisms (SNPs; rs10735810/FokI, rs1544410/BsmI, rs7975232/ApaI, and rs731236/TaqI) in the VDR gene were genotyped in 179 individuals with schizophrenia and 189 healthy controls. No significant associations were detected between any of the four VDR SNPs and risk of schizophrenia. Patients were slightly but significantly shorter compared to controls. Of the four SNPs, only rs10735810/FokI was associated with any of the anthropometric measures: the M4 isoform of this SNP was significantly associated with larger head size (P = 0.002). In light of the evidence demonstrating a role for vitamin D during brain development, the association between polymorphisms in VDR and brain development warrants closer scrutiny.
- Published
- 2006
- Full Text
- View/download PDF
32. Radioactive waste disposal implications of extending Part IIA of the Environmental Protection Act to cover radioactively contaminated land.
- Author
-
Nancarrow DJ and White MM
- Subjects
- Humans, United Kingdom, Radiation Protection legislation & jurisprudence, Radioactive Waste, Soil Pollutants, Radioactive analysis, Waste Management standards
- Abstract
A short study has been carried out of the potential radioactive waste disposal issues associated with the proposed extension of Part IIA of the Environmental Protection Act 1990 to include radioactively contaminated land, where there is no other suitable existing legislation. It was found that there is likely to be an availability problem with respect to disposal at landfills of the radioactive wastes arising from remediation. This is expected to be principally wastes of high volume and low activity (categorised as low level waste (LLW) and very low level waste (VLLW)). The availability problem results from a lack of applications by landfill operators for authorisation to accept LLW wastes for disposal. This is apparently due to perceived adverse publicity associated with the consultation process for authorisation coupled with uncertainty over future liabilities. Disposal of waste as VLLW is limited both by questions over volumes that may be acceptable and, more fundamentally, by the likely alpha activity of wastes (originating from radium and thorium operations). Authorised on-site disposal has had little attention in policy and guidance in recent years, but may have a part to play, especially if considered commercially attractive. Disposal at BNFL's near surface disposal facility for LLW at Drigg is limited to wastes for which there are no practical alternative disposal options (and preference has been given to operational type wastes). Therefore, wastes from the radioactively contaminated land (RCL) regime are not obviously attractive for disposal to Drigg. Illustrative calculations have been performed based on possible volumes and activities of RCL arisings (and assuming Drigg's future volumetric disposal capacity is 950,000 m3). These suggest that wastes arising from implementing the RCL regime, if all disposed to Drigg, would not represent a significant fraction of the volumetric capacity of Drigg, but could have a significant impact on the radiological capacity with respect to 226Ra plus 232Th. The government's decision-making programme for managing solid radioactive wastes in the UK may possibly achieve a general consensus that the use of landfill for LLW from the RCL regime has a fundamental role to play. However, this is unlikely to change the situation within the next few years. No new national facility arising from this programme is likely to be available during the first decade of the operation of a new RCL regime. Hence it appears that Drigg will need to play an important role for some years to come.
- Published
- 2004
- Full Text
- View/download PDF
33. Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia-Pacific region.
- Author
-
Handoko HY, Nancarrow DJ, Hayward NK, Ohaeri JU, Aghanwa H, McGrath JJ, Levinson DF, Johns C, Walters MK, Nertney DA, Srinivasan TN, Thara R, and Mowry BJ
- Subjects
- Australia, Fiji, Humans, Promoter Regions, Genetic, Haplotypes, Schizophrenia genetics, Tumor Necrosis Factor-alpha genetics
- Abstract
A single nucleotide polymorphism (TNF(-308A)) within the promoter region of the gene encoding tumor necrosis factor (TNF), has been significantly associated with schizophrenia in a study of Italian patients and control subjects Boin et al. [2001: Mol Psychiatry 6:79-82]. We have applied case-control analyses to examine TNF promoter haplotypes (containing TNF(-308) and two additional promoter variants: TNF(-376) and TNF(-238)) in four schizophrenia cohorts drawn from Australian, Indian Fijian, Indigenous Fijian, and Brahmin populations. In addition, we have applied the sibling transmission disequilibrium (STD) test to promoter haplotypes within 81 trios drawn from Australian Caucasian pedigrees with multiple schizophrenia cases, and 86 trios drawn from the Brahmin population of Tamil Nadu province in Southern India. Within each of these cohorts, we found no evidence of recombination between these tightly linked promoter variants, supporting previous studies which demonstrated that only a subset of the eight possible haplotypes exist. Of the four observed haplotypes, we and others have observed only one carries the TNF(-308A) variant allele. We report no significant differences in TNF promoter haplotype frequencies between the patient and control groups within each population, although the Indian Fijian cohort showed a trend towards reduced TNF(-308A) alleles amongst schizophrenia cases (P = 0.07). We found no evidence of bias in TNF promoter haplotype transmission to schizophrenia probands. Very similar results were obtained when only the TNF(-308) polymorphism was considered. Taken together, these data provide no support for the involvement of TNF promoter variants TNF(-308), TNF(-376), and TNF(-238) in schizophrenia susceptibility within four ethnically distinct cohorts., (Copyright 2003 Wiley-Liss, Inc.)
- Published
- 2003
- Full Text
- View/download PDF
34. Molecular genetics of schizophrenia.
- Author
-
Mowry BJ and Nancarrow DJ
- Subjects
- Animals, Humans, Phenotype, Receptor, Serotonin, 5-HT2A, Receptors, Dopamine D3, Risk Factors, Schizophrenia diagnosis, Chromosome Mapping methods, Polymorphism, Single Nucleotide genetics, Receptors, Dopamine D2 genetics, Receptors, Serotonin genetics, Schizophrenia genetics
- Abstract
1. Schizophrenia is a chronic, disabling brain disease that affects approximately 1% of the world's population. It is characterized by delusions, hallucinations and formal thought disorder, together with a decline in socio-occupational functioning. While the causes for schizophrenia remain unknown, evidence from family, twin and adoption studies clearly demonstrates that it aggregates in families, with this clustering largely attributable to genetic rather than cultural or environmental factors. Identifying the genes involved, however, has proven to be a difficult task because schizophrenia is a complex trait characterized by an imprecise phenotype, the existence of phenocopies and the presence of low disease penetrance. 2. The current working hypothesis for schizophrenia causation is that multiple genes of small to moderate effect confer compounding risk through interactions with each other and with non-genetic risk factors. The same genes may be commonly involved in conferring risk across populations or they may vary in number and strength between different populations. To search for evidence of such genetic loci, both candidate gene and genome-wide linkage studies have been used in clinical cohorts collected from a variety of populations. Collectively, these works provide some evidence for the involvement of a number of specific genes (e.g. the 5-hydroxytryptamine (5-HT) type 2a receptor (5-HT2a) gene and the dopamine D3 receptor gene) and as yet unidentified factors localized to specific chromosomal regions, including 6p, 6q, 8p, 13q and 22q. These data provide suggestive, but no conclusive, evidence for causative genes. 3. To enable further progress there is a need to: (i) collect fine-grained clinical datasets while searching the schizophrenia phenotype for subgroups or dimensions that may provide a more direct route to causative genes; and (ii) integrate recent refinements in molecular genetic technology, including modern composite marker maps, DNA expression assays and relevant animal models, while using the latest analytical techniques to extract maximum information in order to help distinguish a true result from a false-positive finding.
- Published
- 2001
- Full Text
- View/download PDF
35. Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample.
- Author
-
Mowry BJ, Ewen KR, Nancarrow DJ, Lennon DP, Nertney DA, Jones HL, O'Brien MS, Thornley CE, Walters MK, Crowe RR, Silverman JM, Endicott J, Sharpe L, Hayward NK, Gladis MM, Foote SJ, and Levinson DF
- Subjects
- Alleles, Chromosome Mapping, Chromosomes, Human, Pair 10 genetics, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 2 genetics, Chromosomes, Human, Pair 4 genetics, Chromosomes, Human, Pair 9 genetics, Family Health, Female, Gene Frequency, Genetic Linkage, Genotype, Humans, Male, Microsatellite Repeats, Software, Genome, Human, Schizophrenia genetics
- Abstract
In a previous genome scan of 43 schizophrenia pedigrees, nonparametric linkage (NPL) scores with empirically derived pointwise P-values less than 0.01 were observed in two regions (chromosomes 2q12-13 and 10q23) and less than 0.05 in three regions (4q22-23, 9q22, and 11q21). Markers with a mean spacing of about 5 cM were typed in these regions in an expanded sample of 71 pedigrees, and NPL analyses carried out. No region produced significant genomewide evidence for linkage. On chromosome 10q, the empirical P-value remained at less than 0.01 for the entire sample (D10S168), evidence in the original 43 pedigrees was slightly increased, and a broad peak of positive results was observed. P-values less than 0.05 were observed on chromosomes 2q (D2S436) and 4q (D4S2623), but not on chromosomes 9q or 11q. It is concluded that this sample is most supportive of linkage on chromosome 10q, with less consistent support on chromosomes 2q and 4q. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:864-869, 2000., (Copyright 2000 Wiley-Liss, Inc.)
- Published
- 2000
36. No support for linkage to the bipolar regions on chromosomes 4p, 18p, or 18q in 43 schizophrenia pedigrees.
- Author
-
Nancarrow DJ, Levinson DF, Taylor JM, Hayward NK, Walters MK, Lennon DP, Nertney DA, Jones HL, Mahtani MM, Kirby A, Kruglyak L, Brown DM, Crowe RR, Andreasen NC, Black DW, Silverman JM, Mohs RC, Siever LJ, Endicott J, Sharpe L, and Mowry BJ
- Subjects
- Humans, Pedigree, Bipolar Disorder genetics, Chromosomes, Human, Pair 18 genetics, Chromosomes, Human, Pair 4 genetics, Genetic Linkage genetics, Schizophrenia genetics
- Published
- 2000
37. Follow-up study on a susceptibility locus for schizophrenia on chromosome 6q.
- Author
-
Martinez M, Goldin LR, Cao Q, Zhang J, Sanders AR, Nancarrow DJ, Taylor JM, Levinson DF, Kirby A, Crowe RR, Andreasen NC, Black DW, Silverman JM, Lennon DP, Nertney DA, Brown DM, Mowry BJ, Gershon ES, and Gejman PV
- Subjects
- Female, Follow-Up Studies, Genotype, Humans, Lod Score, Male, Microsatellite Repeats, Models, Statistical, Psychotic Disorders genetics, Chromosomes, Human, Pair 6, Genetic Predisposition to Disease, Schizophrenia genetics
- Abstract
Evidence for suggestive linkage to schizophrenia with chromosome 6q markers was previously reported from a two-stage approach. Using nonparametric affected sib pairs (ASP) methods, nominal p-values of 0.00018 and 0.00095 were obtained in the screening (81 ASPs; 63 independent) and the replication (109 ASPs; 87 independent) data sets, respectively. Here, we report a follow-up study of this 50cM 6q region using 12 microsatellite markers to test for linkage to schizophrenia. We increased the replication sample size by adding an independent sample of 43 multiplex pedigrees (66 ASPs; 54 independent). Pairwise and multipoint nonparametric linkage analyses conducted in this third data set showed evidence consistent with excess sharing in this 6q region, though the statistical level is weaker (p=0.013). When combining both replication data sets (total of 141 independent ASPs), an overall nominal p-value=0.000014 (LOD=3. 82) was obtained. The sibling recurrence risk (lambdas) attributed to this putative 6q susceptibility locus is estimated to be 1.92. The linkage region could not be narrowed down since LOD score values greater than three were observed within a 13cM region. The length of this region was only slightly reduced (12cM) when using the total sample of independent ASPs (204) obtained from all three data sets. This suggests that very large sample sizes may be needed to narrow down this region by ASP linkage methods. Study of the etiological candidate genes in this region is ongoing., (Copyright 1999 Wiley-Liss, Inc.)
- Published
- 1999
38. Genome scan of schizophrenia.
- Author
-
Levinson DF, Mahtani MM, Nancarrow DJ, Brown DM, Kruglyak L, Kirby A, Hayward NK, Crowe RR, Andreasen NC, Black DW, Silverman JM, Endicott J, Sharpe L, Mohs RC, Siever LJ, Walters MK, Lennon DP, Jones HL, Nertney DA, Daly MJ, Gladis M, and Mowry BJ
- Subjects
- Chromosomes, Human genetics, Family, Genetic Linkage, Genetic Markers, Genetic Predisposition to Disease, Genotype, Humans, Microsatellite Repeats, Pedigree, Schizophrenia epidemiology, Chromosome Mapping, Schizophrenia genetics
- Abstract
Objective: The goal of this study was to identify chromosomal regions likely to contain schizophrenia susceptibility genes., Method: A genomewide map of 310 microsatellite DNA markers with average spacing of 11 centimorgans was genotyped in 269 individuals--126 of them with schizophrenia-related psychoses--from 43 pedigrees. Nonparametric linkage analysis was used to assess the pattern of allele sharing at each marker locus relative to the presence of disease., Results: Nonparametric linkage scores did not reach a genomewide level of statistical significance for any marker. There were five chromosomal regions in which empirically derived p values reached nominal levels of significance at eight marker locations. There were p values less than 0.01 at chromosomes 2q (with the peak value in this region at D2S410) and 10q (D10S1239), and there were p values less than 0.05 at chromosomes 4q (D4S2623), 9q (D9S257), and 11q (D11S2002)., Conclusions: The results do not support the hypothesis that a single gene causes a large increase in the risk of schizophrenia. The sample (like most others being studied for psychiatric disorders) has limited power to detect genes of small effect or those that are determinants of risk in a small proportion of families. All of the most positive results could be due to chance, or some could reflect weak linkage (genes of small effect). Multicenter studies may be useful in the effort to identify chromosomal regions most likely to contain schizophrenia susceptibility genes.
- Published
- 1998
- Full Text
- View/download PDF
39. The molecular genetics of schizophrenia: an update.
- Author
-
Mowry BJ, Nancarrow DJ, and Levinson DF
- Subjects
- Chromosome Mapping, Genetic Linkage, Humans, Molecular Biology, Phenotype, Risk Factors, Schizophrenia genetics
- Abstract
Objective: This paper aims to summarise the latest molecular genetic findings in schizophrenia, while providing background information on a number of relevant methodological issues., Method: Accumulative genetic data indicate that schizophrenia is a genetically complex disease with an unclear mode of transmission. The development and rapid progression of molecular genetics have provided a wide variety of methods to search for genes predisposing to human disease. The genetic basis for a number of the simpler diseases has been identified and characterised using these methods. More recently, progress has been made in identifying genes predisposing to the genetically more complex diseases such as diabetes mellitus, multiple sclerosis, bipolar disorder and schizophrenia., Results: The latest findings on chromosomes 3, 6, 8, 13, 18 and 22 and on the X chromosome are reviewed., Conclusions: There is now suggestive support for three susceptibility loci (6p24-22, 8p22-21 and 22q12-q13.1) for schizophrenia, and it is likely that other regions will emerge from studies now in progress. Finding and then characterising genes within these loci will require long-term commitment and systematic efforts in clinical, laboratory and analytical fields.
- Published
- 1997
- Full Text
- View/download PDF
40. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene.
- Author
-
Dann J, DeLisi LE, Devoto M, Laval S, Nancarrow DJ, Shields G, Smith A, Loftus J, Peterson P, Vita A, Comazzi M, Invernizzi G, Levinson DF, Wildenauer D, Mowry BJ, Collier D, Powell J, Crowe RR, Andreasen NC, Silverman JM, Mohs RC, Murray RM, Walters MK, Lennon DP, and Crow TJ
- Subjects
- Chromosome Mapping, Cohort Studies, Genes, Dominant genetics, Genes, Recessive genetics, Genetic Markers genetics, Humans, Lod Score, Models, Genetic, Schizophrenia diagnosis, Genetic Linkage genetics, Monoamine Oxidase genetics, Schizophrenia genetics, Schizophrenic Psychology, Sex Chromosome Aberrations genetics, X Chromosome
- Abstract
A sex chromosome locus for psychosis has been considered on the basis of some sex differences in genetic risk and expression of illness, and an association with X-chromosome anomalies. Previous molecular genetic studies produced weak evidence for linkage of schizophrenia to the proximal short arm of the X-chromosome, while some other regions were not ruled out. Here we report an attempt to expand the Xp findings in: (i) a multicenter collaboration focusing on 92 families with a maternal pattern of inheritance (Study I), and (ii) an independent sample of 34 families unselected for parental mode of transmission (Study II). In the multicenter study, a parametric analysis resulted in positive lod scores (highest of 1.97 for dominant and 1.19 for recessive inheritance at a theta of 0.20) for locus DXS7, with scores below 0.50 for other markers in this region (MAOB, DXS228, and ARAF1). Significant allele sharing among affected sibling pairs was present at DXS7. In the second study, positive lod scores were observed at MAOB (highest of 2.16 at a theta of 0.05 for dominant and 1.64 at a theta of 0.00 for recessive models) and ALAS2 (the highest of 1.36 at a theta of 0.05 for a recessive model), with significant allele sharing (P = 0.003 and 0.01, respectively) at these two loci. These five markers are mapped within a small region of Xp11. Thus, although substantial regions of the X-chromosome have been investigated without evidence for linkage being found, a locus predisposing to schizophrenia in the proximal short arm of the X-chromosome is not excluded.
- Published
- 1997
- Full Text
- View/download PDF
41. Affected-only multiplex pedigree analysis of GAW10 problem 2.
- Author
-
Nancarrow DJ and Mowry BJ
- Subjects
- Chromosome Mapping methods, Computer Simulation, Female, Haplotypes, Humans, Linkage Disequilibrium, Male, Nuclear Family, Pedigree, Statistics, Nonparametric, Genetic Testing methods, Genome, Human, Quantitative Trait, Heritable, Software
- Abstract
From a single extended pedigree simulation replicate, high density, affected only subpedigrees were isolated, based on the T > 40 affected status for the disease trait, Q1. On this sample of 14 pedigrees, with a range of two to six affected members (48 total), we conducted a haplotype based, multilocus, nonparametric genome-wide search of the provided data (367 markers) using the computer program GENEHUNTER. As with most genome screens in complex diseases, the objective of this strategy was to identify regions (hot-spots) which breached our predetermined threshold (p < 0.05), requiring confirmation by other groups or consortia. Of the six regions with threshold breaching scores (p < 0.05), the most promising, on chromosome 8 and chromosome 4, corresponded to the locations of MG2 and MG3. Both of these regions have multiple, consecutive markers above threshold and contained the only scores that exceeded p < 0.01. In addition, a fourth hot-spot consisting of a single marker above threshold, was less than 15 cM from MG1 on chromosome 5. The positions of the remaining three hot-spots did not correspond to the any of the major genes and are therefore false positives. An additional analysis of a single nuclear pedigree simulation replicate, using the extended transmission disequilibrium test (ETDT), was applied to markers in each of the above hot-spot regions to look for evidence of disequilibrium with the disease trait. This analysis provided weak additional support for the chromosome 8 finding, even though the sample was very small (36 pedigrees containing 44 affected offspring).
- Published
- 1997
- Full Text
- View/download PDF
42. Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families.
- Author
-
Grimmond SM, Palmer JM, Walters MK, Scott C, Nancarrow DJ, Teh BT, Elmes C, Pyke C, Khoo SK, Bennett I, Wetzig N, and Hayward NK
- Subjects
- Australia, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Male genetics, Chromosomes, Human, Pair 17 genetics, Female, Genetic Linkage genetics, Genetic Predisposition to Disease, Haplotypes genetics, Humans, Male, Neoplasms genetics, Pedigree, Polymerase Chain Reaction, Polymorphism, Genetic genetics, Repetitive Sequences, Nucleic Acid, Risk Factors, Breast Neoplasms genetics, Chromosomes, Human, Pair 13 genetics, Genetic Markers genetics, Neoplasm Proteins genetics, Transcription Factors genetics
- Abstract
Two major genes determining predisposition to breast cancer, termed BRCA1 and BRCA2, have been mapped to the long arms of chromosomes 17 and 13, respectively. Each locus is believed to account for approximately 40% of cases of familial breast cancer. We used linkage and haplotype analysis with simple tandem repeat polymorphisms at chromosomal bands 17q21 and 13q12 to determine the contribution of the BRCA1 and BRCA2 genes to predisposition to breast cancer in four Australian breast cancer kindreds, one of which had two male cousins with breast cancer. Surprisingly all families segregated a haplotype of markers on 13q and showed positive lod scores supporting linkage to BRCA2. In addition, haplotype analysis identified an informative recombination between D13S260 and D13S171 in one affected individual, which refines the localisation of BRCA2 to between D13S260 and D13S267; a distance of 2-3 cM. Tumours of the stomach and cervix, as well as melanoma and leukaemia/lymphoma also occur in these pedigrees but the numbers are too low to determine whether they may be significantly associated with BRCA2 carrier status. Our results confirm the existence of BRCA2 on the long arm of chromosome 13 and support previous findings that this locus is likely to confer risk in families with affected males. Furthermore, our observations suggest that the BRCA2 gene may also contribute to the development of other neoplasma.
- Published
- 1996
- Full Text
- View/download PDF
43. Deletion mapping of the short arm of chromosome 3 in Merkel cell carcinoma.
- Author
-
Leonard JH, Williams G, Walters MK, Nancarrow DJ, and Rabbitts PH
- Subjects
- Cell Line, Transformed, Chromosome Mapping, Chromosomes, Human, Pair 3 ultrastructure, DNA, Neoplasm genetics, Herpesvirus 4, Human, Humans, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Sequence Deletion, Skin Neoplasms ultrastructure, Tumor Cells, Cultured, Carcinoma, Merkel Cell genetics, Chromosomes, Human, Pair 3 genetics, Skin Neoplasms genetics
- Abstract
Little is known about the biology of Merkel cell carcinoma (MCC), also called small cell carcinoma of the skin. MCC has similarities with small cell lung cancer (SCLC): both are neuroendocrine malignancies with early metastasis to distant sites and a poor prognosis. Small cell lung cancer biopsies are known to have frequent losses on chromosome 3 in the region 3p21, yet MCCs have not been reported to have 3p deletions by karyotypic analysis. Considering the similarities between SCLC and MCC, we investigated 26 MCC tumours for loss of heterozygosity (LOH) on 3p. First, RFLP analysis was performed using PCR with nine primer sets from six loci. Second, 25 tumours were examined by microsatellite analysis for 3p markers D3S1289 and D3S1285 and SST on 3q. All 26 tumours were informative at one or more loci; of these, 18 (69%) demonstrated LOH for at least one marker on the short arm. For all informative loci the frequency of LOH was greater than 30% (range 33-75%). In a cell line derived from one tumour, it was possible to demonstrate rearrangement of chromosome 3 by in situ hybridisation. No LOH was seen in 15 informative cases for the 3q locus SST. A region 3p13-p21.1, centered on the marker D3S2, was deleted in all tumours demonstrating LOH, with a secondary deletion involving D3S30 detected in some tumours at 3p13. Our results indicate that LOH on 3p is a common occurrence in MCC; however, three tumours for which DNA was also available from a corresponding cell line suggest there may be a subset of MCC whose genesis is independent of deletions of 3p.
- Published
- 1996
- Full Text
- View/download PDF
44. Schizophrenia susceptibility and chromosome 6p24-22.
- Author
-
Mowry BJ, Nancarrow DJ, Lennon DP, Sandkuijl LA, Crowe RR, Silverman JM, Mohs RC, Siever LJ, Endicott J, and Sharpe L
- Subjects
- Genetic Heterogeneity, Humans, Lod Score, Pedigree, Chromosomes, Human, Pair 6, Schizophrenia genetics
- Published
- 1995
- Full Text
- View/download PDF
45. The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population.
- Author
-
Maw MA, Allen-Powell DR, Goodey RJ, Stewart IA, Nancarrow DJ, Hayward NK, and Gardner RJ
- Subjects
- Base Sequence, Chromosome Mapping, Connexin 26, Connexins, DNA analysis, Genetic Markers, Humans, Lod Score, Molecular Sequence Data, Pedigree, White People genetics, Chromosomes, Human, Pair 13, Deafness genetics, Genetic Linkage, Genetics, Population
- Abstract
Classical studies have demonstrated genetic heterogeneity for nonsyndromic autosomal recessive congenital neurosensory deafness, with at least six loci postulated. Linkage analysis in two consanguineous Tunisian kindreds has demonstrated that one such deafness locus, DFNB1, maps near chromosome 13 markers D13S175, D13S143, and D13S115. We tested these markers for cosegregation with deafness in 18 New Zealand and 1 Australian nonconsanguineous kindreds, each of which included at least two siblings with nonsyndromic presumed congenital sensorineural deafness and that had a pedigree structure consistent with autosomal recessive inheritance. When all families were combined, a peak two-point lod score of 2.547 (theta = .1) was obtained for D13S175, 0.780 (theta = .2) for D13S143, and 0.664 (theta = .3) for D13S115. While there was no statistically significant evidence for heterogeneity at any of the three loci tested, nine families showed cosegregation of marker haplotypes with deafness. These observations suggest that the DFNB1 locus may make an important contribution to autosomal recessive neurosensory deafness in a Caucasian population. In the nine cosegregating families, phenotypic variation was observed both within sibships (in four families), which indicates that variable expressivity characterizes some genotypes at the DFNB1 locus, and between generations (in two families), which suggests allelic heterogeneity.
- Published
- 1995
46. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p.
- Author
-
Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber JL, and Hayward NK
- Subjects
- Chromosome Mapping, Disease Susceptibility, Family, Genetic Markers, Genotype, HLA Antigens genetics, Haplotypes genetics, Humans, Queensland, Western Australia, Chromosomes, Human, Pair 6 genetics, Lod Score, Melanoma genetics
- Abstract
Malignant melanoma occurs as a familial cancer in 5%-10% of cases, where it segregates in a manner consistent with autosomal dominant inheritance. Evidence from cytogenetics, fine mapping studies of deletions in melanomas and recent linkage studies supports the location of a human melanoma predisposition gene on the short arm of chromosome 9. Evidence also exists for a melanoma gene on Ip, indicating genetic heterogeneity for melanoma predisposition. Previous studies have also reported findings suggestive of linkage of some melanoma families to the HLA region on the short arm of chromosome 6 (6p), indicating the possibility of even greater heterogeneity. To further define the possible effect of a gene within the HLA region on melanoma susceptibility, we have typed 7 simple tandem repeat polymorphisms (STRPs) from 6p in 16 Australian melanoma kindreds. Maximum 2-point LOD scores ranged from 1.13 (theta = 0.2) to 2.03 (theta = 0.15) for 4 contiguous markers flanking the HLA complex, and multi-point analysis gave a peak LOD score of 1.64, 24 centimorgans telomeric to D6S109. However, extended haplotype analysis of these markers showed that a region between D6S105 and HLAF segregated with melanoma in 5/16 families. These results are surprising given that the same cohort of families has previously been shown to be linked to chromosome 9. One interpretation of the current findings is that melanoma susceptibility in some families may result from a gene mapping within the HLA region of chromosome 6p.
- Published
- 1994
- Full Text
- View/download PDF
47. Multiple endocrine neoplasia type 1 (MEN1) in two Asian families.
- Author
-
Teh BT, Hii SI, David R, Parameswaran V, Grimmond S, Walters MK, Tan TT, Nancarrow DJ, Chan SP, and Mennon J
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoid Tumor genetics, Child, Chromosomes, Human, Pair 11, Female, Genetic Testing, Humans, Malaysia, Male, Multiple Endocrine Neoplasia Type 1 ethnology, Pedigree, Polymorphism, Genetic, Asian People genetics, Endocrine Gland Neoplasms genetics, Lod Score, Multiple Endocrine Neoplasia Type 1 genetics
- Abstract
Multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disease characterized by neoplasia of the parathyroid glands, anterior pituitary and endocrine pancreas, is rarely reported in Asian populations. The MEN1 gene, mapped to chromosome 11q13 but yet to be cloned, has been found to be homogeneous in Caucasian populations through linkage analysis. Here, two previously unreported Asian kindreds with MEN1 are described; linkage analysis using microsatellite polymorphic markers in the MEN1 region was carried out. The first kindred, of Mongolian-Chinese origin, is a multigeneration family with over 150 living members, eight of whom are affected to date. The second kindred is of Chinese origin consisting of four affected members. Linkage to chromosome 11q13 was confirmed in both kindreds, supporting evidence for genetic homogeneity. A recombination in the larger kindred localizes the gene distal to marker D11S956, consistent with its placement from previous studies. We also show that it is feasible to use these markers for predictive testing, as four gene carriers were detected in 13 family members with unknown disease status in the first kindred.
- Published
- 1994
- Full Text
- View/download PDF
48. Microsatellite instability in melanoma.
- Author
-
Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, and Hayward NK
- Subjects
- Humans, DNA, Neoplasm genetics, Melanoma genetics, Mutation genetics, Repetitive Sequences, Nucleic Acid
- Published
- 1994
- Full Text
- View/download PDF
49. Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma.
- Author
-
Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, and Hayward NK
- Subjects
- DNA, Neoplasm genetics, Genetic Markers, Heterozygote, Humans, Tumor Cells, Cultured, Alleles, Chromosome Deletion, Chromosomes, Human, Pair 6, Melanoma genetics, Repetitive Sequences, Nucleic Acid
- Abstract
Karyotypic analysis, loss of somatic heterozygosity, microcell fusion and cDNA transfection studies have provided compelling evidence that at least one tumour suppressor gene for melanoma resides on chromosome 6. In an attempt to further define the regions to which these putative suppressor genes map, we have carried out loss of heterozygosity (LOH) studies on DNA from 25 fresh melanoma tumours for 9 simple tandem repeat (STR) polymorphism markers spanning chromosome 6. Four samples displayed LOH or homozygosity for all markers studied, indicating that they had lost one homologue of chromosome 6. An additional 3 samples showed LOH for all markers on 6q. Furthermore, 30 melanoma cell lines, for which there were no matching somatic DNA samples, were analyzed for hemizygosity of markers on 6q. One cell line had a homozygous deletion of all markers tested and a further 12 cell lines displayed only one allele for 3 or 4 contiguous markers, indicating that most, if not all of these samples were hemizygous for the region of 6q distal to D6S87. Overall, the rate of LOH on 6q in the 55 melanoma DNAs was 35%, and there were no losses of markers on 6p without concomitant loss of markers on 6q. Two of 5 samples derived from primary melanomas showed LOH, which indicates that LOH for the melanoma suppressor gene on 6q, which maps to a region that contains the SOD2 locus, is a frequent and early event in melanoma tumorigenesis.
- Published
- 1994
- Full Text
- View/download PDF
50. Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions.
- Author
-
Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, and Hayward NK
- Subjects
- Alleles, Chromosome Mapping methods, Gene Deletion, Heterozygote, Homozygote, Humans, Polymorphism, Genetic, Repetitive Sequences, Nucleic Acid, Tumor Cells, Cultured, Chromosomes, Human, Pair 9, Melanoma genetics
- Abstract
Various lines of evidence including linkage analysis, frequent homozygous and heterozygous deletions in melanoma DNAs, and the finding of a patient with multiple primary melanomas who harbours a 5p/9p translocation involving loss of several 9p markers, have indicated that the 9p22-p13 region harbours a gene important for the development of melanoma (MLM). We have used eight short tandem repeat polymorphism (STRP) markers mapping to this region to look for allelic losses in DNA from melanoma biopsies and cell lines. Heterozygous losses were found in 8/14 (57%) fresh melanoma biopsy DNAs with the smallest region of overlap (SRO) being between IFNA and D9S169. In addition, when DNA from 30 melanoma cell lines was studied, four cell lines (13%) were found to be homozygously deleted for various 9p markers. Two of these cell lines define the borders of overlapping homozygous deletions within a 4cM region of 9p21 between IFNA and D9S171. Moreover, a further 14 melanoma cell lines were hemizygous for the IFNA/D9S171/D9S126 region. These data support the hypothesis that the MLM gene acts as a tumour suppressor, and provide a refinement of its localization on 9p.
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.